BidaskClub upgraded shares of Seres Therapeutics (NASDAQ:MCRB) from a strong sell rating to a sell rating in a report issued on Friday, April 13th.
Separately, Zacks Investment Research lowered shares of Seres Therapeutics from a buy rating to a hold rating in a report on Wednesday, January 3rd. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating to the stock. The stock currently has an average rating of Buy and a consensus price target of $18.00.
Shares of MCRB opened at $7.73 on Friday. The company has a current ratio of 4.90, a quick ratio of 4.90 and a debt-to-equity ratio of 0.15. Seres Therapeutics has a twelve month low of $6.65 and a twelve month high of $17.42.
Seres Therapeutics (NASDAQ:MCRB) last announced its quarterly earnings results on Thursday, March 8th. The biotechnology company reported ($0.71) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.73) by $0.02. The business had revenue of $3.06 million during the quarter, compared to analysts’ expectations of $3.00 million. Seres Therapeutics had a negative net margin of 278.44% and a negative return on equity of 103.46%. research analysts expect that Seres Therapeutics will post -2.65 EPS for the current fiscal year.
A number of hedge funds and other institutional investors have recently modified their holdings of the business. ARK Investment Management LLC raised its holdings in Seres Therapeutics by 82.0% in the 4th quarter. ARK Investment Management LLC now owns 1,625,501 shares of the biotechnology company’s stock worth $16,483,000 after purchasing an additional 732,579 shares in the last quarter. Renaissance Technologies LLC raised its holdings in Seres Therapeutics by 48.7% in the 4th quarter. Renaissance Technologies LLC now owns 911,200 shares of the biotechnology company’s stock worth $9,240,000 after purchasing an additional 298,300 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in Seres Therapeutics by 39.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 373,334 shares of the biotechnology company’s stock worth $6,160,000 after purchasing an additional 106,479 shares in the last quarter. Millennium Management LLC raised its holdings in Seres Therapeutics by 40.3% in the 4th quarter. Millennium Management LLC now owns 295,675 shares of the biotechnology company’s stock worth $2,998,000 after purchasing an additional 84,936 shares in the last quarter. Finally, Jennison Associates LLC bought a new position in Seres Therapeutics in the 4th quarter worth $2,308,000. Institutional investors and hedge funds own 79.02% of the company’s stock.
TRADEMARK VIOLATION WARNING: This story was published by The Lincolnian Online and is owned by of The Lincolnian Online. If you are reading this story on another domain, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The correct version of this story can be accessed at https://www.thelincolnianonline.com/2018/04/22/seres-therapeutics-mcrb-stock-rating-upgraded-by-bidaskclub.html.
Seres Therapeutics Company Profile
Seres Therapeutics, Inc is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company’s drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome.
Receive News & Ratings for Seres Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.